期刊文献+

miR-155在胃癌组织中的表达及临床意义

The expression of miR - 155 in gastric carcinoma and its clinical significance
下载PDF
导出
摘要 目的分析胃癌组织和癌旁组织miR-155的表达差异及其临床意义。方法收集手术切除的胃癌标本52例,采用实时荧光定量聚合酶链反应(RT—PCR)检测胃癌组织及癌旁组织标本miR-155的表达水平,并分析其表达水平与临床病理因素的关系。结果miR-155在胃癌组织中的表达量显著高于其在配对癌旁组织中的表达量(P〈0.05);淋巴结转移组的表达量高于淋巴结未转移组(P〈0.05)。结论miR-155可能在胃癌发生、发展和转移过程中起到重要作用。 Objective To investigate the expression of miR - 155 in gastric carcinoma and its clinical significance. Methods 52 pairs of human gastric tissue samples were obtained from patients who underwent surgical resection. The level of miR - 155 in 52 gastric carcinoma samples and the adjacent normal tissue samples was quantified by real - time reverse transcriptase - polymerase chain reaction ( RT - PCR) and the relationship between miR - 155 level and clinical and pathological factors were explored. Results The expression of miR - 155 in gastric cancer tissues was significantly increased than that in the adjacent normal tissues (P 〈 0.05). The up - regulation expression of miR - 155 was associated with lymph node metastases in gastric carcinoma patients (P 〈 0.05). Conclusion miR - 155 may play an important role in the development and metastasis of gastric carcinoma.
出处 《徐州医学院学报》 CAS 2013年第5期331-333,共3页 Acta Academiae Medicinae Xuzhou
基金 基金项目:江苏省卫生厅面上科研项目(H201220) 江苏省普通高校研究生科研创新计划项目(CXLX11_0742)
关键词 胃癌 实时荧光定量聚合酶链反应 MIR-155 gastric carcinoma real- time PCR miR- 155
  • 相关文献

参考文献4

二级参考文献12

  • 1Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world.Clin Oncol,2006,24:2137-2150.
  • 2Bartel DP.MicroRNA:genomics,biogenesis,mechanism,and function.Cell,2004,116:281-297.
  • 3Felekkis K,Touvana E,Stefanou CH,et al.microRNAs:a newly described class of encoded molecules that play a role in health and disease.Hippokrata,2010,14:236-240.
  • 4Takagi T,Lio A,Nakagawa Y,et al.Decreased expression of microRNA-143 and-145 in human gastric cancers.Oneology,2009,77:12-21.
  • 5Mudd PA, Teague BN, Farris AD. Regulatory T cells and systemic lupus erythematosus [ J]. Scand J Immunol, 2006,64 ( 3 ) :211 -218.
  • 6Suen JL, Li HT, Jong YJ, et al. Altered homeostasis of CD4 + Foxp3 + regulatory T cell subpopulations in systemic lupus erythematosus [ J ]. Immunology, 2009,127 (2) : 196 - 205.
  • 7Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation [ J]. Nat Rev Immunol, 2007,7 (6) : 454 - 465.
  • 8Kubo M, Hanada T, Yoshimura A. Suppessors of eytokine signalling and immunity [J]. Nat Immunol, 2003,4( 12): 1169 - 1176.
  • 9Waiboei LW, Ahmed CM, Mujtaba MG, et al. Both the suppressor of cytokine signaling 1 ( SOCS - 1 ) kinase inhibitory region and SOCS - 1 mimetie bind to JAK2 autophosphorylation site : implications for the development of a SOCS - 1 antagonist [ J]. J Immunol, 2007,178(8) : 5058 -5068.
  • 10Matsumura Y, Kobayashi T, Ichiyama K, et al. Selective expan- sion of foxp3 - positive regulatory T ceils and immunosuppression by suppressors of cytokine signaling 3 - deficient dendritic cells [J]. J Immunol, 2007, 179(4) : 2170 -2179.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部